Nuclear Medicine

Gastrointestinal Cancers

Questions discussed in this category

Would you consider 177Lu-Dotatate (Lutathera) in patients with midgut neuroendocrine carcinoma after treatment with a somatostatin analog but with Ki67 >20%?

This patient had a Ki67 of 27%. However, the inclusion criteria for the NETTER-1 Trial was Ki67<20%. Would Lutathera be an option if labs are withi...

2 Answers available

Can PRRT be used in a patient with a GI neuroendocrine tumor and estimated GFR of less than 30?

1 Answer available

Papers discussed in this category

Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2005-01

Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate.

J. Nucl. Med.,

NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of Lu-DOTATATE Peptide Receptor Radionuclide Therapy.

Neuroendocrinology, 2017 Apr 13

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues.

Endocr Relat Cancer,

Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study.

J Nucl Med, 2018 Aug 16

Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.

Eur J Nucl Med Mol Imaging, 2017 Sep 12

Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis.

Nuclear Medicine

Gastrointestinal Cancers

Questions discussed in this category

Papers discussed in this category

Related Topics in Nuclear Medicine